Gapping up
In reaction to earnings/guidance:
- SNAP +23.1%, CALX +14.8%, TCS +9.4%, ERIC +8.3%, AN +8%, WDFC +7.3%, SCL +6.4%, USNA +5%, REXR +4.7%, UCBI +4%, LAD +3.8%, IPG +3.6%, HOPE +3%, HWC +2.8%, PNFP +2.8%, WGO +2.8%, FBC +2.7%, EVR +1.6%, TMO +1.6%, NDAQ +1.6%, CADE +1.5%, NEP +1.5%, AVY +1.3%, BKR +1.3%, ABT +1.1%, SLGN +1%, TER +0.9%, TXN +0.8%
Other news:
- PNM +7.8% (PNM Resources to be acquired by AVANGRID (AGR) for $50.30 per share)
- PRTA +6.6% (PRTA and RHHBY to advance prasinezumab into late-stage clinical development study in Parkinson's disease)
- ATNM +6.4% (awarded grant from National Institutes of Health to study Iomab-ACT targeted conditioning with CD19 CAR T-Cell therapy)
- XERS +5.9% (FDA grants Fast Track designation for XP-0863)
- OCX +5.1% (announces DetermaRx testing volumes more than doubled in Q3)
- TGTX +3.8% (granted FDA Fast Track Designation to the combination of ublituximab) GM +2% (introduces 2022 GMC Hummer EV sport utility truck starting at $112,595, according to CNBC)
- PSTH +1.2% (Michael Bloomberg in talks to sell minority stake in Bloomberg LP to Pershing Square, according to the NY Post)
- PHR +1.2% (prices underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $32.00 per share)
Analyst comments:
- PINS +8.2% (in sympathy with SNAP earnings report; names former DIS exec to board; also upgraded to Buy from Neutral at Goldman and upgraded to Buy from Neutral at BofA Securities)
- AAP +1.9% (upgraded to Outperform from Mkt Perform at Raymond James)
- PLAY +1.6% (upgraded to Strong Buy from Outperform at Raymond James)
- JCI +1.5% (upgraded to Outperform from Perform at Oppenheimer)
- ALB +1.4% (upgraded to Buy from Hold at HSBC Securities)
- PAYC +0.9% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)